Ark Therapeutics completes manufacturing of PsiOxus drug

Ark Therapeutics has completed the cGMP (current good manufacturing practices) manufacturing and release of a new developmental drug product for PsiOxus Therapeutics.

The compound was created under a stringent timescale at Ark's facility in Finland using a proprietary suspension-based single-use process called Atosus, allowing it to meet the necessary quality standards in less than 12 months.

It will now be utilised in a phase I clinical trial of the oncolytic vaccine ColoAd1, which is currently under development by PsiOxus for the treatment of colorectal cancer.

According to Ark, this success demonstrates Atosus' effectiveness as a reliable and cost-effective platform for adenoviral manufacturing.

Dr David Venables, chief executive officer of Ark, said: "We are delighted that our continued success in the manufacture of ColoAd1 will enable the development of this exciting product to progress on schedule."

The company's partnership with PsiOxus is one of its most strategically important alliances, with other current Ark partners including Merck Millipore.